STOCKHOLM, Feb. 15, 2018 /PRNewswire/ --
Fourth Quarter
- Revenue increased by 18.7% to €181.2m (€152.7m). Organic
revenue grew by 13.6%.
- Operating profit amounted to €7.5m (€7.8m), representing an
operating margin of 4.1% (5.1%).
- Net profit amounted to €3.9m (€9.2m), which represents a net
profit margin of 2.2% (6.0%).
- EBITDA increased by 11.0% to €16.2m (€14.6m), corresponding to
an EBITDA margin of 8.9% (9.6%).
- Adjusted EBITDA increased by 18.9% to €17.6m (€14.8m),
corresponding to an adjusted EBITDA margin of 9.7% (9.7%).
- Cash flow from operating activities amounted to €8.7m
(€17.3m).
Full Year
- Revenue increased by 15.8% to €671.6m (€580.2m). Organic
revenue grew by 13.5%.
- Operating profit amounted to €29.4m (€28.8m), representing an
operating margin of 4.4% (5.0%).
- Net profit increased by 31.2% to €26.5m (€20.2m), which
represents a net profit margin of 3.9% (3.5%).
- EBITDA increased by 8.7% to €59.8m (€55.0m), corresponding to
an EBITDA margin of 8.9% (9.5%).
- Adjusted EBITDA increased by 9.5% to €63.2m (€57.7m),
corresponding to an adjusted EBITDA margin of 9.4% (9.9%).
- Cash flow from operating activities amounted to €44.4m
(€50.3m).
- Basic/diluted earnings per share (EPS) were €0.185
(€0.157).
- Members increased by 185,000 to 1.2 million, the strongest
growth ever.
- The Board of Directors proposes that no dividend is paid for
the financial year 2018, in line with dividend guidance.
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q4
2018
|
Q4
2017
|
Growth
|
FY
2018
|
FY
2017
|
Growth
|
|
Revenue
|
181.2
|
152.7
|
19%
|
671.6
|
580.2
|
16%
|
|
Operating
profit
|
7.5
|
7.8
|
-4%
|
29.4
|
28.8
|
2%
|
|
Operating profit
margin, %
|
4.1%
|
5.1%
|
|
4.4%
|
5.0%
|
|
|
Net profit
|
3.9
|
9.2
|
-58%
|
26.5
|
20.2
|
31%
|
|
Net profit margin,
%
|
2.2%
|
6.0%
|
|
3.9%
|
3.5%
|
|
|
Earnings per share,
€
|
0.025
|
0.067
|
-63%
|
0.185
|
0.157
|
18%
|
|
Diluted earnings per
share, €
|
0.025
|
0.067
|
-63%
|
0.185
|
0.157
|
18%
|
|
|
|
|
|
|
|
|
EBITDA
|
16.2
|
14.6
|
11%
|
59.8
|
55.0
|
9%
|
|
EBITDA margin,
%
|
8.9%
|
9.6%
|
|
8.9%
|
9.5%
|
|
For definition and reconciliation of alternative performance
measures, refer to note 13.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication, through
the agency of the contact person set out below, at 8.00 CET on
15 February 2019. This interim report
and other information about Medicover, is available at
medicover.com
Medicover is a leading international healthcare and diagnostic
services company and was founded in 1995. Medicover operates a
large number of ambulatory clinics, hospitals, specialty-care
facilities and laboratories and the largest markets are
Poland and Germany. In 2017, Medicover had revenue around
€580 million and 15,900 employees. For more information, go to
www.medicover.com
Contact information
For further
information, please contact:
Hanna Bjellquist, Head of Investor
Relations
Phone: +46-70-303-32-72
E-mail: hanna.bjellquist@medicover.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/medicover/r/year-end-report-january-december-2018,c2741907
The following files are available for download:
|
https://mb.cision.com/Main/15662/2741907/991698.pdf
|
Year-end report
January-December 2018
|
